E. Tang

Community assessment of cancer drug combination screens identifies strategies for synergy prediction

Tin Chi Nguyen, Robert M. Vogel, M. Zaslavskiy, 2017, bioRxiv.

A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination prediction

Robert M. Vogel, M. Zaslavskiy, Y. Guan, 2018 .

Achieving Accurate Compound Concentration in Cell-Based Screening: Validation of Acoustic Droplet Ejection Technology

R. J. Grant, E. Tang, K. Roberts, 2009, Journal of biomolecular screening.

Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines

E. Tang, T. Petreuș, U. Polanska, 2015, Cell Death and Disease.

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models

E. Tang, B. Davies, T. Klinowska, 2015, International journal of oncology.

Naphthyl ketones: a new class of Janus kinase 3 inhibitors.

D. S. James, E. Tang, G. R. Brown, 2000, Bioorganic & medicinal chemistry letters.

Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen

Robert M. Vogel, M. Zaslavskiy, Y. Guan, 2019, Nature Communications.

Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen

Amir K. Foroushani, Yuanfang Guan, Jaewoo Kang, 2019, Nature Communications.